JP2008245990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008245990A5 JP2008245990A5 JP2007092193A JP2007092193A JP2008245990A5 JP 2008245990 A5 JP2008245990 A5 JP 2008245990A5 JP 2007092193 A JP2007092193 A JP 2007092193A JP 2007092193 A JP2007092193 A JP 2007092193A JP 2008245990 A5 JP2008245990 A5 JP 2008245990A5
- Authority
- JP
- Japan
- Prior art keywords
- electrode
- ttdp
- frequency power
- antenna probe
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004020 conductor Substances 0.000 claims description 320
- 239000000523 sample Substances 0.000 claims description 92
- 230000001225 therapeutic effect Effects 0.000 claims description 71
- 230000008878 coupling Effects 0.000 claims description 56
- 238000010168 coupling process Methods 0.000 claims description 56
- 238000005859 coupling reaction Methods 0.000 claims description 56
- 239000003814 drug Substances 0.000 claims description 52
- 229940079593 drug Drugs 0.000 claims description 50
- 230000005540 biological transmission Effects 0.000 claims description 43
- 229910052594 sapphire Inorganic materials 0.000 claims description 42
- 239000010980 sapphire Substances 0.000 claims description 42
- 239000012212 insulator Substances 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 239000000463 material Substances 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 238000005520 cutting process Methods 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 230000003902 lesion Effects 0.000 claims description 10
- 239000000693 micelle Substances 0.000 claims description 7
- 230000001093 anti-cancer Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 238000005476 soldering Methods 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 125000003827 glycol group Chemical group 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 229960001221 pirarubicin Drugs 0.000 claims description 2
- 230000037237 body shape Effects 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims 1
- 229960001674 tegafur Drugs 0.000 claims 1
- RWLRWONNIHIYGR-UHFFFAOYSA-N 18-[[3,5-bis[1-[17-carboxyheptadecyl(methyl)amino]ethyl]-2-hydroxyphenyl]methyl-methylamino]nonadecanoic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(C)N(C)CC1=CC(C(C)N(C)CCCCCCCCCCCCCCCCCC(O)=O)=CC(C(C)N(C)CCCCCCCCCCCCCCCCCC(O)=O)=C1O RWLRWONNIHIYGR-UHFFFAOYSA-N 0.000 description 294
- 210000001519 tissue Anatomy 0.000 description 125
- 230000005855 radiation Effects 0.000 description 30
- 238000000034 method Methods 0.000 description 29
- 238000000015 thermotherapy Methods 0.000 description 26
- 238000012986 modification Methods 0.000 description 19
- 230000004048 modification Effects 0.000 description 19
- 238000010586 diagram Methods 0.000 description 18
- 238000009826 distribution Methods 0.000 description 14
- 101000795744 Homo sapiens TPA-induced transmembrane protein Proteins 0.000 description 13
- 102100031626 TPA-induced transmembrane protein Human genes 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 13
- 238000000576 coating method Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 238000010292 electrical insulation Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 229910052751 metal Inorganic materials 0.000 description 11
- 239000002184 metal Substances 0.000 description 11
- 238000005452 bending Methods 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 9
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 9
- 239000004810 polytetrafluoroethylene Substances 0.000 description 9
- 206010020843 Hyperthermia Diseases 0.000 description 8
- 244000052616 bacterial pathogen Species 0.000 description 8
- 239000002826 coolant Substances 0.000 description 8
- 230000036031 hyperthermia Effects 0.000 description 8
- 238000009413 insulation Methods 0.000 description 8
- 230000017074 necrotic cell death Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 229910000679 solder Inorganic materials 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 239000011810 insulating material Substances 0.000 description 7
- 238000004904 shortening Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 239000004800 polyvinyl chloride Substances 0.000 description 6
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 229920000915 polyvinyl chloride Polymers 0.000 description 5
- 238000002679 ablation Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000003754 machining Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000013021 overheating Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- -1 polytetrafluoroethylene Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010067268 Post procedural infection Diseases 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012809 cooling fluid Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 239000011253 protective coating Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000007674 radiofrequency ablation Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101710162453 Replication factor A Proteins 0.000 description 1
- 102100035729 Replication protein A 70 kDa DNA-binding subunit Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005404 monopole Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000000615 nonconductor Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229920009441 perflouroethylene propylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000010248 power generation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007092193A JP5156893B2 (ja) | 2007-03-30 | 2007-03-30 | 高周波治療器、高周波治療システムおよびそれらの使用方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007092193A JP5156893B2 (ja) | 2007-03-30 | 2007-03-30 | 高周波治療器、高周波治療システムおよびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008245990A JP2008245990A (ja) | 2008-10-16 |
| JP2008245990A5 true JP2008245990A5 (enExample) | 2010-05-20 |
| JP5156893B2 JP5156893B2 (ja) | 2013-03-06 |
Family
ID=39971653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007092193A Expired - Fee Related JP5156893B2 (ja) | 2007-03-30 | 2007-03-30 | 高周波治療器、高周波治療システムおよびそれらの使用方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5156893B2 (enExample) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5957671A (ja) * | 1982-09-27 | 1984-04-03 | 呉羽化学工業株式会社 | 医用極超短波アンテナ |
| JP2852084B2 (ja) * | 1989-09-26 | 1999-01-27 | オリンパス光学工業株式会社 | 医療用マイクロ波プローブ |
| JPH07185019A (ja) * | 1993-12-27 | 1995-07-25 | Olympus Optical Co Ltd | 温熱治療装置 |
| JP2001037775A (ja) * | 1999-07-26 | 2001-02-13 | Olympus Optical Co Ltd | 治療装置 |
| JP4138468B2 (ja) * | 2002-12-06 | 2008-08-27 | アルフレッサファーマ株式会社 | マイクロ波手術器 |
| JP4438338B2 (ja) * | 2003-07-28 | 2010-03-24 | 株式会社村田製作所 | 同軸プローブ |
| JP2007029457A (ja) * | 2005-07-27 | 2007-02-08 | Univ Nihon | マイクロ波凝固療法用同軸アンテナ |
-
2007
- 2007-03-30 JP JP2007092193A patent/JP5156893B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7864129B2 (en) | Radio frequency medical treatment device and system and usage method thereof | |
| JP6464230B2 (ja) | 柔軟な流体冷却シャフトを備えたエネルギー伝達装置、それと共に使用するのに適した流入／流出接合部およびそれらを含むシステム | |
| JP6587669B2 (ja) | 柔軟な流体冷却シャフトを備えたエネルギー伝達装置、それと共に使用するのに適した流入／流出接合部およびそれらを含むシステム | |
| JP6195694B2 (ja) | 柔軟な流体冷却シャフトを備えたエネルギー伝達装置、それと共に使用するのに適した流入／流出接合部およびそれらを含むシステム | |
| US11944376B2 (en) | Transmission line with heat transfer ability | |
| JP6072409B2 (ja) | 柔軟な流体冷却シャフトを備えたエネルギー伝達装置、それと共に使用するのに適した流入／流出接合部およびそれらを含むシステム | |
| JP5776929B2 (ja) | アンテナ放射部分の大気曝露のためのバラン構造を有する電気外科手術装置およびそれを用いてエネルギーを組織に導く方法 | |
| JP6122239B2 (ja) | 使用者によって制御される移相を有するデュアルアンテナアセンブリ | |
| AU2017202771B2 (en) | Ablation instruments with a member having a triangular cross-section | |
| JP5156893B2 (ja) | 高周波治療器、高周波治療システムおよびそれらの使用方法 | |
| JP6314200B2 (ja) | マイクロ波場検出ニードルアセンブリ、その製造方法、それを用いた組織内照射焼灼領域の調節方法およびそれを含むシステム | |
| JP2008245990A5 (enExample) | ||
| JP5055500B2 (ja) | 治療用アンテナプローブとその使用方法及び電磁治療システム | |
| US20190125444A1 (en) | Systems and methods for ablating tissue |